Does Ozempic shrink your heart muscle? What the science says

What did @thedarkhorsepodcast actually say?

Heather Heying claimed there is evidence of "heart muscle size reduction and heart muscle cell reduction in people who take Ozempic regardless of whether or not they lost weight." The specific worry she raised: even people who are not obese and do not lose weight on semaglutide still lose heart muscle mass and heart muscle cells. Her conclusion was blunt: "That's bad."

This is a meaningful distinction from the broader muscle-loss conversation. Most critics of GLP-1 drugs focus on lean mass loss tied to rapid weight loss. Heying is making a narrower, more alarming claim: that cardiac muscle atrophy happens independent of weight change. That's a specific mechanistic claim and it deserves a specific answer, not a vague reassurance.

Does the science back this up?

Partially, but the framing is more alarming than the current evidence warrants. There is real signal here, but it is being presented as settled when it is not.

A 2024 study by Carbone et al. published in JACC: Heart Failure did find reductions in left ventricular mass in patients with heart failure with preserved ejection fraction (HFpEF) taking semaglutide, which was part of the STEP-HFpEF trial. Separately, preclinical data from rodent studies have raised questions about cardiomyocyte size with GLP-1 receptor agonist exposure. However, the reduction in cardiac mass seen in human trials has largely been interpreted by cardiologists as favorable, not harmful, because obesity itself causes pathological cardiac enlargement. Losing some of that excess mass is generally considered a good outcome.

The claim that non-obese people on semaglutide lose cardiac muscle mass without losing weight is not well-established in peer-reviewed human data as of mid-2024. Heying may be extrapolating from animal data or early preprints, which is a significant leap.

What did they get wrong (or right)?

Heying gets partial credit for raising a real question about cardiac effects beyond weight-related changes. The concern about lean mass loss, including muscle generally, is legitimate and documented. Wilding et al. (2021, NEJM) confirmed meaningful lean mass loss alongside fat loss in STEP-1 trial participants.

But the specific claim that people "who aren't obese don't lose weight, but they still lose heart muscle mass" is not supported by robust human clinical data. The cardiac imaging studies that exist are almost entirely in overweight or obese populations, or people with established heart failure. Applying those findings to lean, healthy users is speculative.

She also conflates two different things: reduction in pathologically enlarged cardiac mass (which cardiologists largely welcome) versus loss of healthy myocardial tissue (which would genuinely be alarming). Treating them as the same thing misleads the audience about the clinical stakes.

What should you actually know?

The honest answer is that long-term cardiac safety data for semaglutide in healthy-weight users is still limited. Most cardiovascular outcome trials, including SUSTAIN-6 and SELECT, enrolled people with existing cardiovascular disease or obesity. We do not have strong prospective data on cardiac morphology in lean individuals using GLP-1 agonists off-label.

What we do know: GLP-1 receptors are expressed in cardiac tissue. Some preclinical studies suggest these drugs have direct effects on the heart beyond weight loss. Whether those effects are net positive, neutral, or harmful in healthy people is genuinely unresolved. That is worth saying clearly. Raising the question is fair. Presenting it as established evidence of harm is not.

If you are taking semaglutide or considering it, this is a legitimate topic to bring to a physician. It is not a reason to panic, but it is also not nothing.